Notch1 transcriptional complex inhibitors

Notch1 transcriptional complex inhibitors are a class of small molecule therapeutic candidates being developed by StemSynergy Therapeutics for the treatment of Notch-driven cancers. Unlike traditional gamma-secretase inhibitors (GSIs) that inhibit the proteolytic cleavage of all four Notch receptors, these compounds are designed to specifically disrupt the assembly or function of the Notch1 transcriptional activation complex. This complex typically consists of the Notch1 intracellular domain (NICD1), the DNA-binding protein CSL (CBF1/RBPJ), and the co-activator Mastermind-like (MAML). By targeting the transcriptional complex directly, these inhibitors aim to block the expression of oncogenic Notch target genes while minimizing the gastrointestinal toxicities often associated with pan-Notch inhibition. The program is currently in preclinical development, with compounds such as SSTN-101 demonstrating efficacy in models of T-cell acute lymphoblastic leukemia (T-ALL).

Other names

Notch1 transcriptional complex inhibitor programNotch-1 transcriptional complex inhibitor programNotch 1 transcriptional complex inhibitor program